210 related articles for article (PubMed ID: 23875016)
21. Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.
Smith DD; Saetrom P; Snøve O; Lundberg C; Rivas GE; Glackin C; Larson GP
BMC Bioinformatics; 2008 Jan; 9():63. PubMed ID: 18226260
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.
Fackler MJ; Umbricht CB; Williams D; Argani P; Cruz LA; Merino VF; Teo WW; Zhang Z; Huang P; Visvananthan K; Marks J; Ethier S; Gray JW; Wolff AC; Cope LM; Sukumar S
Cancer Res; 2011 Oct; 71(19):6195-207. PubMed ID: 21825015
[TBL] [Abstract][Full Text] [Related]
23. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.
Wang C; Mayer JA; Mazumdar A; Brown PH
Breast Cancer Res Treat; 2012 Jun; 133(2):487-500. PubMed ID: 21947652
[TBL] [Abstract][Full Text] [Related]
24. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
Liu D; Zhou K
Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
[TBL] [Abstract][Full Text] [Related]
25. Comparative expression analysis of four breast cancer subtypes versus matched normal tissue from the same patients.
Martini PG; Taylor DM; Bienkowska J; Jackson J; McAllister G; Keilhack H; Campbell RK
J Steroid Biochem Mol Biol; 2008 Apr; 109(3-5):207-11. PubMed ID: 18424034
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
[TBL] [Abstract][Full Text] [Related]
27. ER
Guerrero-Zotano AL; Stricker TP; Formisano L; Hutchinson KE; Stover DG; Lee KM; Schwarz LJ; Giltnane JM; Estrada MV; Jansen VM; Servetto A; Gavilá J; Perez-Fidalgo JA; Lluch A; Llombart-Cussac A; Bayar MA; Michiels S; André F; Arnedos M; Guillem V; Ruiz-Simon A; Arteaga CL
Clin Cancer Res; 2018 Jun; 24(11):2517-2529. PubMed ID: 29581135
[No Abstract] [Full Text] [Related]
28. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
Osborne JR; Port E; Gonen M; Doane A; Yeung H; Gerald W; Cook JB; Larson S
J Nucl Med; 2010 Apr; 51(4):543-50. PubMed ID: 20237034
[TBL] [Abstract][Full Text] [Related]
29. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes.
Dutta B; Pusztai L; Qi Y; André F; Lazar V; Bianchini G; Ueno N; Agarwal R; Wang B; Shiang CY; Hortobagyi GN; Mills GB; Symmans WF; Balázsi G
Br J Cancer; 2012 Mar; 106(6):1107-16. PubMed ID: 22343619
[TBL] [Abstract][Full Text] [Related]
30. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer.
Frasor J; Weaver A; Pradhan M; Dai Y; Miller LD; Lin CY; Stanculescu A
Cancer Res; 2009 Dec; 69(23):8918-25. PubMed ID: 19920189
[TBL] [Abstract][Full Text] [Related]
31. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression.
Ferguson AT; Lapidus RG; Baylin SB; Davidson NE
Cancer Res; 1995 Jun; 55(11):2279-83. PubMed ID: 7538900
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data.
Xiao B; Zhang W; Chen L; Hang J; Wang L; Zhang R; Liao Y; Chen J; Ma Q; Sun Z; Li L
Gene; 2018 Jun; 658():28-35. PubMed ID: 29518546
[TBL] [Abstract][Full Text] [Related]
33. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
Tian X; Zhang Z
IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
[TBL] [Abstract][Full Text] [Related]
34. Identification of key genes relevant to the prognosis of ER-positive and ER-negative breast cancer based on a prognostic prediction system.
Xiao B; Hang J; Lei T; He Y; Kuang Z; Wang L; Chen L; He J; Zhang W; Liao Y; Sun Z; Li L
Mol Biol Rep; 2019 Apr; 46(2):2111-2119. PubMed ID: 30888555
[TBL] [Abstract][Full Text] [Related]
35. How to target estrogen receptor-negative breast cancer?
Rochefort H; Glondu M; Sahla ME; Platet N; Garcia M
Endocr Relat Cancer; 2003 Jun; 10(2):261-6. PubMed ID: 12790787
[TBL] [Abstract][Full Text] [Related]
36. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
Rody A; Holtrich U; Pusztai L; Liedtke C; Gaetje R; Ruckhaeberle E; Solbach C; Hanker L; Ahr A; Metzler D; Engels K; Karn T; Kaufmann M
Breast Cancer Res; 2009; 11(2):R15. PubMed ID: 19272155
[TBL] [Abstract][Full Text] [Related]
37. Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.
Lu Y; You M; Ghazoui Z; Liu P; Vedell PT; Wen W; Bode AM; Grubbs CJ; Lubet RA
Cancer Prev Res (Phila); 2013 Nov; 6(11):1151-61. PubMed ID: 24067424
[TBL] [Abstract][Full Text] [Related]
38. Challenges in projecting clustering results across gene expression-profiling datasets.
Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
[No Abstract] [Full Text] [Related]
40. Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.
Yau C; Fedele V; Roydasgupta R; Fridlyand J; Hubbard A; Gray JW; Chew K; Dairkee SH; Moore DH; Schittulli F; Tommasi S; Paradiso A; Albertson DG; Benz CC
Breast Cancer Res; 2007; 9(5):R59. PubMed ID: 17850661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
